CWM Advisors LLC reduced its stake in shares of The Medicines Company (NASDAQ:MDCO) by 41.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 3,018 shares of the company’s stock after selling 2,122 shares during the period. CWM Advisors LLC’s holdings in The Medicines were worth $256,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors also recently made changes to their positions in the stock. Strs Ohio increased its holdings in The Medicines by 47.2% in the 4th quarter. Strs Ohio now owns 13,100 shares of the company’s stock worth $1,112,000 after acquiring an additional 4,200 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of The Medicines by 13.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,407 shares of the company’s stock worth $459,000 after purchasing an additional 648 shares during the period. Vertex One Asset Management Inc. bought a new position in shares of The Medicines in the fourth quarter worth approximately $3,601,000. Nisa Investment Advisors LLC boosted its position in shares of The Medicines by 83.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 5,330 shares of the company’s stock worth $453,000 after purchasing an additional 2,430 shares during the period. Finally, Quad Capital Management Advisors LLC purchased a new stake in shares of The Medicines in the fourth quarter worth $734,000.
Shares of NASDAQ MDCO opened at $84.90 on Friday. The company has a debt-to-equity ratio of 21.45, a quick ratio of 0.77 and a current ratio of 0.77. The company has a market cap of $6.77 billion, a P/E ratio of -29.18 and a beta of 1.10. The firm’s fifty day moving average is $84.68 and its two-hundred day moving average is $57.72. The Medicines Company has a 52-week low of $17.81 and a 52-week high of $84.98.
The Medicines (NASDAQ:MDCO) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.12). During the same period last year, the firm posted ($0.70) EPS. As a group, analysts forecast that The Medicines Company will post -3.42 EPS for the current fiscal year.
Several brokerages have recently commented on MDCO. Svb Leerink downgraded shares of The Medicines from an “outperform” rating to a “market perform” rating and raised their price objective for the company from $78.00 to $85.00 in a research report on Tuesday, November 26th. Leerink Swann downgraded shares of The Medicines from an “outperform” rating to a “market perform” rating in a report on Wednesday, November 27th. ValuEngine lowered The Medicines from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. BidaskClub raised The Medicines from a “hold” rating to a “buy” rating in a report on Thursday, November 21st. Finally, Citigroup restated a “hold” rating and issued a $59.00 price objective on shares of The Medicines in a research report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the stock. The Medicines currently has an average rating of “Hold” and an average target price of $72.57.
About The Medicines
The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels.
Further Reading: What are no-load funds?
Want to see what other hedge funds are holding MDCO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Medicines Company (NASDAQ:MDCO).
Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.